Genes That Affect Disease Outcome in Patients With Metastatic Colorectal Cancer
NCT ID: NCT00467129
Last Updated: 2013-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
800 participants
OBSERVATIONAL
2002-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is examining genes that affect disease outcome in patients with metastatic colorectal cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
NCT00537823
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
NCT06226857
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
NCT00006479
Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200
NCT00897819
Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients
NCT02055560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Collect blood samples for DNA extraction for genetic studies from patients receiving chemotherapy for metastatic colorectal cancer.
* Collect detailed clinical, pathological, and chemotherapy data from these patients.
* Identify genetic factors that relate to treatment response and outcome in these patients.
OUTLINE: Blood samples are collected and relevant genes and regions are amplified by PCR. PCR products are then sequenced or genotyped for known biological markers and single nucleotide polymorphisms. Tumor samples from surplus pathology specimens are analyzed for expression of candidate genes and mutation in the candidate genes.
Clinical and family history data is also collected by questionnaire.
PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
microarray analysis
mutation analysis
polymerase chain reaction
polymorphism analysis
laboratory biomarker analysis
questionnaire administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of metastatic colorectal cancer
* Currently receiving chemotherapy at Weston Park Hospital
PATIENT CHARACTERISTICS:
* Not Specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sheffield
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angela Cox, PhD
Role: STUDY_CHAIR
University of Sheffield
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEFF-SSREC01/271
Identifier Type: -
Identifier Source: secondary_id
SHEFF-USMS-SSREC01/271
Identifier Type: -
Identifier Source: secondary_id
EU-20727
Identifier Type: -
Identifier Source: secondary_id
CDR0000540670
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.